Symptomtext
PROQUAD was inadvertently administered with VARIVAX; No additional Adverse Event (AE) details; PROQUAD was inadvertently administered with VARIVAX instead of MMR-II; This spontaneous report was received from a health professional referring to an unknown age and gender patient. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies, and concomitant therapies were not reported. On 18-JUL-2022, the measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant human albumin (rHA)) (PROQUAD) subcutaneous injection, lot number W004028, expiration date: 02-AUG-2023 was inadvertently administered with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, lot number U016064, expiration date: 20-MAY-2023, and sterile diluent, solution for injection/infusion, lot number W000443 which was determined to be valid with expiration date: 20-APR-2024, instead of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection; all vaccines were administered subcutaneously for prophylaxis (strength, dose and anatomical site were not provided) (wrong product administered) (accidental overdose). No additional adverse event (AE) information was provided (no adverse event).